Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome

Journal of Autoimmunity

Volumn 39, Issue 1-2, 2012, Pages 103-111

  Abdulahad, Wayel H ^a   Kroese, Frans G M ^a   Vissink, Arjan ^a   Bootsma, Hendrika ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

B cell; Primary Sj gren's syndrome; Rituximab; T cell

Indexed keywords

ALPHA INTERFERON; APRIL PROTEIN; B CELL ACTIVATING FACTOR; BETA INTERFERON; CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; HELPER CELL; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SJOEGREN SYNDROME; T LYMPHOCYTE; TH17 CELL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LACRIMAL APPARATUS; LYMPHOCYTE DEPLETION; SALIVARY GLANDS; SJOGREN'S SYNDROME; T-LYMPHOCYTES;

EID: 84862496764     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.01.009     Document Type: Review

References (101)

1. Fox R.I. Sjogren's syndrome. Lancet 2005 Jul 23, 366(9482):321-331.
2. Mavragani C.P., Tzioufas A.G., Moutsopoulos H.M. Sjogren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol 2000 Sep, 123(1):46-57.
3. Hansen A., Lipsky P.E., Dorner T. B-cells in Sjogren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007, 9(4):218.
4. Kassan S.S., Thomas T.L., Moutsopoulos H.M., Hoover R., Kimberly R.P., Budman D.R., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978 Dec, 89(6):888-892.
5. Baimpa E., Dahabreh I.J., Voulgarelis M., Moutsopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009 Sep, 88(5):284-293.
6. Pijpe J., Meijer J.M., Bootsma H., van der Wal J.E., Spijkervet F.K., Kallenberg C.G., et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. Arthritis Rheum 2009 Nov, 60(11):3251-3256.
7. Meijer J.M., Meiners P.M., Vissink A., Spijkervet F.K., Abdulahad W., Kamminga N., et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010 Apr, 62(4):960-968.
8. Varin M.M., Le P.L., Youinou P., Saulep D., Mackay F., Pers J.O. B-cell tolerance breakdown in Sjogren's syndrome: focus on BAFF. Autoimmun Rev 2010 Jul, 9(9):604-608.
9. Trinchieri G. Type I interferon: friend or foe?. J Exp Med 2010 Sep 27, 207(10):2053-2063.
10. Onishi S., Nagashima T., Kimura H., Matsuyama Y., Yoshio T., Minota S. Systemic lupus erythematosus and Sjogren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus 2010 May, 19(6):753-755.
11. Zheng L., Zhang Z., Yu C., Tu L., Zhong L., Yang C. Association between IFN-alpha and primary Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009 Jan, 107(1):e12-e18.
12. Bave U., Nordmark G., Lovgren T., Ronnelid J., Cajander S., Eloranta M.L., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005 Apr, 52(4):1185-1195.
13. Gottenberg J.E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci U S A 2006 Feb 21, 103(8):2770-2775.
14. Vogelsang P., Brun J.G., Oijordsbakken G., Skarstein K., Jonsson R., Appel S. Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis 2010 Jun, 69(6):1235-1238.
15. Mavragani C.P., Crow M.K. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010 Nov, 35(3):225-231.
16. Ittah M., Miceli-Richard C., Gottenberg J.E., Sellam J., Eid P., Lebon P., et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008 Apr, 38(4):1058-1064.
17. Hjelmervik T.O., Petersen K., Jonassen I., Jonsson R., Bolstad A.I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005 May, 52(5):1534-1544.
18. Wildenberg M.E., van Helden-Meeuwsen C.G., van de Merwe J.P., Drexhage H.A., Versnel M.A. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008 Jul, 38(7):2024-2033.
19. Emamian E.S., Leon J.M., Lessard C.J., Grandits M., Baechler E.C., Gaffney P.M., et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009 Jun, 10(4):285-296.
20. Fox R.I., Pearson G., Vaughan J.H. Detection of Epstein-Barr virus-associated antigens and DNA in salivary gland biopsies from patients with Sjogren's syndrome. J Immunol 1986 Nov 15, 137(10):3162-3168.
21. Nagata Y., Inoue H., Yamada K., Higashiyama H., Mishima K., Kizu Y., et al. Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients. Immunology 2004 Feb, 111(2):223-229.
22. Triantafyllopoulou A., Tapinos N., Moutsopoulos H.M. Evidence for coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum 2004 Sep, 50(9):2897-2902.
23. Ferraccioli G.F., Salaffi F., De V.S., Casatta L., Avellini C., Carotti M., et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 1996 Jul, 14(4):367-371.
24. Shiozawa S., Tanaka Y., Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998 Apr, 18(4):255-262.
25. Ship J.A., Fox P.C., Michalek J.E., Cummins M.J., Richards A.B. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. J Interferon Cytokine Res 1999 Aug, 19(8):943-951. IFN Protocol Study Group.
26. Smith J.K., Siddiqui A.A., Modica L.A., Dykes R., Simmons C., Schmidt J., et al. Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands. J Interferon Cytokine Res 1999 Aug, 19(8):929-935.
27. Mackay F., Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009 Jul, 9(7):491-502.
28. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P. Association of BAFF/BLyS overexpression and altered B-cell differentiation with Sjogren's syndrome. J Clin Invest 2002 Jan, 109(1):59-68.
29. Jonsson M.V., Szodoray P., Jellestad S., Jonsson R., Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005 May, 25(3):189-201.
30. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003 Feb, 62(2):168-171.
31. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005 Jun, 1050:34-39.
32. Szodoray P., Alex P., Jonsson M.V., Knowlton N., Dozmorov I., Nakken B., et al. Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005 Nov, 117(2):168-176.
33. Daridon C., Devauchelle V., Hutin P., Le B.R., Martins-Carvalho C., Bendaoud B., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 2007 Apr, 56(4):1134-1144.
34. d'Arbonneau F., Pers J.O., Devauchelle V., Pennec Y., Saraux A., Youinou P. BAFF-induced changes in B-cell antigen receptor-containing lipid rafts in Sjogren's syndrome. Arthritis Rheum 2006 Jan, 54(1):115-126.
35. Ittah M., Miceli-Richard C., Eric G.J., Lavie F., Lazure T., Ba N., et al. B-cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006, 8(2):R51.
36. Ittah M., Miceli-Richard C., Lebon P., Pallier C., Lepajolec C., Mariette X. Induction of B-cell-activating factor by viral infection is a general phenomenon, but the types of viruses and mechanisms depend on cell type. J Innate Immun 2011, 3(2):200-207.
37. Devauchelle-Pensec V., Cagnard N., Pers J.O., Youinou P., Saraux A., Chiocchia G. Gene expression profile in the salivary glands of primary Sjogren's syndrome patients before and after treatment with rituximab. Arthritis Rheum 2010 Aug, 62(8):2262-2271.
38. Wiglesworth A.K., Ennis K.M., Kockler D.R. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus. Ann Pharmacother 2010 Dec, 44(12):1955-1961.
39. Eilertsen G.O., Van G.M., Strand H., Nossent J.C. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study. Rheumatology (Oxford) 2011 Dec, 50(12):2197-2205.
40. Koyama T., Tsukamoto H., Miyagi Y., Himeji D., Otsuka J., Miyagawa H., et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005 Jul, 64(7):1065-1067.
41. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011 Aug, 70(8):1363-1368.
42. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's syndrome. Arthritis Rheum 1999 Aug, 42(8):1765-1772.
43. Le P.L., Devauchelle V., Fautrel A., Daridon C., Saraux A., Youinou P., et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B-cells. J Immunol 2009 Mar 15, 182(6):3540-3547.
44. Stott D.I., Hiepe F., Hummel M., Steinhauser G., Berek C. Antigen-driven clonal proliferation of B-cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998 Sep 1, 102(5):938-946.
45. Salomonsson S., Wahren-Herlenius M. Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels of circulating antibodies in sera of patients with Sjogren's syndrome. Scand J Rheumatol 2003, 32(2):79-82.
46. Gellrich S., Rutz S., Borkowski A., Golembowski S., Gromnica-Ihle E., Sterry W., et al. Analysis of V(H)-D-J(H) gene transcripts in B-cells infiltrating the salivary glands and lymph node tissues of patients with Sjogren's syndrome. Arthritis Rheum 1999 Feb, 42(2):240-247.
47. Abdulahad W.H., Meijer J.M., Kroese F.G., Meiners P.M., Vissink A., Spijkervet F.K., et al. B-cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjogren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011 Apr, 63(4):1116-1123.
48. Hansen A., Odendahl M., Reiter K., Jacobi A.M., Feist E., Scholze J., et al. Diminished peripheral blood memory B-cells and accumulation of memory B-cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002 Aug, 46(8):2160-2171.
49. Bohnhorst J.O., Bjorgan M.B., Thoen J.E., Natvig J.B., Thompson K.M. Bm1-Bm5 classification of peripheral blood B-cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B-cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001 Oct 1, 167(7):3610-3618.
50. Bohnhorst J.O., Thoen J.E., Natvig J.B., Thompson K.M. Significantly depressed percentage of CD27+ (memory) B-cells among peripheral blood B-cells in patients with primary Sjogren's syndrome. Scand J Immunol 2001 Oct, 54(4):421-427.
51. Binard A., Le P.L., Devauchelle-Pensec V., Saraux A., Youinou P., Pers J.O. Is the blood B-cell subset profile diagnostic for Sjogren syndrome?. Ann Rheum Dis 2009 Sep, 68(9):1447-1452.
52. Amft N., Curnow S.J., Scheel-Toellner D., Devadas A., Oates J., Crocker J., et al. Ectopic expression of the B-cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum 2001 Nov, 44(11):2633-2641.
53. Xanthou G., Polihronis M., Tzioufas A.G., Paikos S., Sideras P., Moutsopoulos H.M. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 2001 Feb, 44(2):408-418.
54. Salomonsson S., Larsson P., Tengner P., Mellquist E., Hjelmstrom P., Wahren-Herlenius M. Expression of the B-cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogren's syndrome. Scand J Immunol 2002 Apr, 55(4):336-342.
55. Barone F., Bombardieri M., Manzo A., Blades M.C., Morgan P.R., Challacombe S.J., et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum 2005 Jun, 52(6):1773-1784.
56. Bohnhorst J.O., Bjorgan M.B., Thoen J.E., Jonsson R., Natvig J.B., Thompson K.M. Abnormal B-cell differentiation in primary Sjogren's syndrome results in a depressed percentage of circulating memory B-cells and elevated levels of soluble CD27 that correlate with Serum IgG concentration. Clin Immunol 2002 Apr, 103(1):79-88.
57. Wirths S., Lanzavecchia A. ABCB1 transporter discriminates human resting naive B-cells from cycling transitional and memory B-cells. Eur J Immunol 2005 Dec, 35(12):3433-3441.
58. Fecteau J.F., Cote G., Neron S. A new memory CD27-IgG+ B-cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. J Immunol 2006 Sep 15, 177(6):3728-3736.
59. Wei C., Anolik J., Cappione A., Zheng B., Pugh-Bernard A., Brooks J., et al. A new population of cells lacking expression of CD27 represents a notable component of the B-cell memory compartment in systemic lupus erythematosus. J Immunol 2007 May 15, 178(10):6624-6633.
60. Duty J.A., Szodoray P., Zheng N.Y., Koelsch K.A., Zhang Q., Swiatkowski M., et al. Functional anergy in a subpopulation of naive B-cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009 Jan 16, 206(1):139-151.
61. Duddy M.E., Alter A., Bar-Or A. Distinct profiles of human B-cell effector cytokines: a role in immune regulation?. J Immunol 2004 Mar 15, 172(6):3422-3427.
62. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le B.R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007 May, 56(5):1464-1477.
63. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005 Sep, 52(9):2740-2750.
64. Meijer J.M., Pijpe J., Vissink A., Kallenberg C.G., Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009 Feb, 68(2):284-285.
65. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007 Mar 15, 57(2):310-317.
66. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B-cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007 Mar, 66(3):351-357.
67. Dass S., Bowman S.J., Vital E.M., Ikeda K., Pease C.T., Hamburger J., et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008 Nov, 67(11):1541-1544.
68. Meiners P.M., Vissink A., Kallenberg C.G., Kroese F.G., Bootsma H. Treatment of primary Sjogren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. Expert Opin Biol Ther 2011 Oct, 11(10):1381-1394.
69. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., et al. Reduced competitiveness of autoantigen-engaged B-cells due to increased dependence on BAFF. Immunity 2004 Apr, 20(4):441-453.
70. Ota M., Duong B.H., Torkamani A., Doyle C.M., Gavin A.L., Ota T., et al. Regulation of the B-cell receptor repertoire and self-reactivity by BAFF. J Immunol 2010 Oct 1, 185(7):4128-4136.
71. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B-cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004 Jun, 20(6):785-798.
72. Blair P.A., Norena L.Y., Flores-Borja F., Rawlings D.J., Isenberg D.A., Ehrenstein M.R., et al. CD19(+)CD24(hi)CD38(hi) B-cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010 Jan 29, 32(1):129-140.
73. Iwata Y., Matsushita T., Horikawa M., Dilillo D.J., Yanaba K., Venturi G.M., et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011 Jan 13, 117(2):530-541.
74. Jousse-Joulin S., Devauchelle-Pensec V., Morvan J., Guias B., Pennec Y., Pers J.O., et al. Ultrasound assessment of salivary glands in patients with primary Sjogren's syndrome treated with rituximab: quantitative and doppler waveform analysis. Biologics 2007 Sep, 1(3):311-319.
75. Seror R., Ravaud P., Bowman S.J., Baron G., Tzioufas A., Theander E., et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010 Jun, 69(6):1103-1109.
76. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005 Jun, 64(6):913-920.
77. Galarza C., Valencia D., Tobon G.J., Zurita L., Mantilla R.D., Pineda-Tamayo R., et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. Clin Rev Allergy Immunol 2008 Feb, 34(1):124-128.
78. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos H.M. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010 Jun, 34(4):400-407.
79. Ogawa N., Ping L., Zhenjun L., Takada Y., Sugai S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum 2002 Oct, 46(10):2730-2741.
80. Yin H., Vosters J.L., Roescher N., D'Souza A., Kurien B.T., Tak P.P., et al. Location of immunization and interferon-gamma are central to induction of salivary gland dysfunction in Ro60 peptide immunized model of Sjogren's syndrome. PLoS One 2011, 6(3):e18003.
81. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003 Feb 13, 421(6924):744-748.
82. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003 Dec 15, 198(12):1951-1957.
83. Nguyen C.Q., Hu M.H., Li Y., Stewart C., Peck A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum 2008 Mar, 58(3):734-743.
84. Sakai A., Sugawara Y., Kuroishi T., Sasano T., Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008 Aug 15, 181(4):2898-2906.
85. Nguyen C.Q., Yin H., Lee B.H., Chiorini J.A., Peck A.B. IL17: potential therapeutic target in Sjogren's syndrome using adenovirus-mediated gene transfer. Lab Invest 2011 Jan, 91(1):54-62.
86. Nguyen C.Q., Yin H., Lee B.H., Carcamo W.C., Chiorini J.A., Peck A.B. Pathogenic effect of interleukin-17A in induction of Sjogren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther 2010, 12(6):R220.
87. Li X., Li X., Qian L., Wang G., Zhang H., Wang X., et al. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjogren's syndrome. J Rheumatol 2007 Dec, 34(12):2438-2445.
88. Liu M.F., Lin L.H., Weng C.T., Weng M.Y. Decreased CD4+CD25+bright T cells in peripheral blood of patients with primary Sjogren's syndrome. Lupus 2008 Jan, 17(1):34-39.
89. Christodoulou M.I., Kapsogeorgou E.K., Moutsopoulos N.M., Moutsopoulos H.M. Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 2008 Nov, 173(5):1389-1396.
90. Gottenberg J.E., Lavie F., Abbed K., Gasnault J., Le N.E., Delfraissy J.F., et al. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjogren's syndrome. J Autoimmun 2005 May, 24(3):235-242.
91. Linterman M.A., Pierson W., Lee S.K., Kallies A., Kawamoto S., Rayner T.F., et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med 2011 Aug, 17(8):975-982.
92. Koenen H.J., Smeets R.L., Vink P.M., van R.E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008 Sep 15, 112(6):2340-2352.
93. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A 2009 Mar 24, 106(12):4793-4798.
94. Beriou G., Costantino C.M., Ashley C.W., Yang L., Kuchroo V.K., Baecher-Allan C., et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009 Apr 30, 113(18):4240-4249.
95. Abdulahad W.H., Boots A.M., Kallenberg C.G. FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells. Rheumatology (Oxford) 2011 Apr, 50(4):646-656.
96. van de Veerdonk F.L., Lauwerys B., Marijnissen R.J., Timmermans K., Di P.F., Koenders M.I., et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011 Jun, 63(6):1507-1516.
97. Eggleton P., Bremer E., Tarr J.M., de B.M., Helfrich W., Kendall A., et al. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res Ther 2011 Dec 15, 13(6):R208.
98. Kallenberg C.G., Vissink A., Kroese F.G., Abdulahad W.H., Bootsma H. What have we learned from clinical trials in primary Sjogren's syndrome about pathogenesis?. Arthritis Res Ther 2011 Feb 28, 13(1):205.
99. Ramos-Casals M., Garcia-Hernandez F.J., de R.E., Callejas J.L., Martinez-Berriotxoa A., Pallares L., et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010 Jul, 28(4):468-476.
100. Devauchelle-Pensec V., Morvan J., Rat A.C., Jousse-Joulin S., Pennec Y., Pers J.O., et al. Effects of rituximab therapy on quality of life in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2011 Jan, 29(1):6-12.
101. Mekinian A., Ravaud P., Hatron P.Y., et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012 Jan, 71(1):84-87.